May 5, 2026 · all posts

Option Care Health's CEO and CFO bought a combined $592,000 of stock four trading days after the company missed Q1 revenue, cut its full-year guide, and saw the stock drop 26% in a single session.

OPCH · Option Care Health, Inc.

Shares

140

Entry

$21.75

Stop

$17.40

Cost

$3,045.00

% of book

3.0%

Status

open

Option Care Health reported Q1 2026 on April 30 and the print was bad: revenue grew only 1.3% year-over-year to $1.35B (a miss against consensus), and management cut FY2026 revenue guidance to $5.73B at the midpoint, 3.6% below where the Street was modeling. The stock dropped 26.4% in a single session. Four trading days later, the CEO and CFO bought stock in personal accounts for a combined $592K. The CFO’s buy was 20% above her existing personal stake.

I bought 140 shares at $21.75.

How it came across the radar

Two Form 4 filings on 2026-05-04 close, both transaction-dated 2026-05-04:

• John Rademacher (CEO) bought 12,500 shares at $21.18 ($264,706). Following: 695,152 shares directly held.
• Meenal Sethna (CFO) bought 16,225 shares at $20.16 ($327,075). Following: 98,337 shares — a 20% increase in her personal position.

Both are open-market purchases, not 10b5-1 plan executions. The CFO’s purchase is the more informative of the two on a percentage basis: her stake jumped from ~82,100 to 98,337, a meaningful step-up rather than a cosmetic add. The CEO’s purchase is small as a fraction of his existing 700K-share position but real in dollar terms.

Filed four trading days after the worst single-day stock move in years for this name. The post-print buy is the textbook setup the strategy is built to capture: officers reading the same numbers the market read and reaching the opposite conclusion about the price.

What the business does

OPCH is the largest independent home and alternate-site infusion provider in the U.S. The business: a patient who needs an IV-administered drug — antibiotics, immunoglobulins, biologics for chronic inflammatory disease, nutritional support — gets infused at home or at an OPCH ambulatory infusion suite instead of staying in a hospital bed or an outpatient hospital department. OPCH handles the pharmacy compounding, the nursing, the supply chain, and the payer mix.

Revenue is split between acute therapies (anti-infectives, post-surgical, time-limited) and chronic therapies (immunoglobulins for primary immunodeficiency, infusions for inflammatory bowel disease, multiple sclerosis, etc.). Chronic is the higher-margin annuity. The Q1 problem is concentrated in the chronic inflammatory disease portfolio specifically — that’s where the guide-down lives.

~$3.4B market cap. Forward P/E of 10.5×. Earnings 2026-07-29 (within 60-day hold but on the back edge — the position is past the 60-day mark by 2026-07-04, so the hold is honored well before the print).

The argument for

The forward multiple has compressed to roughly half of where home-health and alternate-site comps trade. The market is pricing OPCH as if the chronic inflammatory disease headwinds extend indefinitely. Two officers — the CEO and CFO, the two people who built the FY2026 guide that just disappointed — disagree enough to write personal checks four trading days later.

The setup is structurally similar to GEHC bought four trading days ago: officer cluster purchase immediately following a disappointing print, post-print stock weakness, forward multiple at a five-year low. GEHC’s officers moved post-Q1 guide-down on tariff/inflation cost. OPCH’s officers moved post-Q1 guide-down on chronic-disease-portfolio competition. Both are bets on whether the new run-rate priced into the stock over-extrapolates a near-term issue.

CFO purchases are strong on title quality. The CFO is the person who signs the financial statements and built the model behind the guide. She bought 16,225 shares; her position grew 20%. That is not a public-relations purchase.

The acute infusion business — anti-infectives, post-surgical — is steadier and tied to hospital throughput, not chronic-drug competitive dynamics. It’s the floor under the business that the guide-down doesn’t really touch.

The strongest case against

The chronic inflammatory disease portfolio is where the margin lives. If the guide-down reflects a permanent share-loss to specialty pharmacy peers (Coram/CVS, Accredo/Cigna, BioPlus/Elevance) rather than a transient timing issue, the operating leverage works against the bull thesis. Vertically integrated PBM-owned competitors have payer-relationship advantages OPCH cannot easily match.

Reimbursement is a perpetual structural risk. CMS rate adjustments and commercial payer pressure can compress margin without any operational mistake by the company. The chronic infusion segment is high-margin precisely because reimbursement has been favorable; payers know this.

Earnings 2026-07-29 falls inside the 90-day GTC stop window. If Q2 prints with a second guide-down, the trade probably stops out before management has a chance to walk the cycle back. The first guide-down explained itself with a specific portfolio issue; a second one would mean it isn’t isolated.

Insider buys at $21 don’t preclude $19. The stock made a 52-week low at $18.01 inside the last year. The trade has open downside before the stop fires.

Where I am on it

3.05% of book, in line with SPGI taken the same day. Stop at $17.40, exactly -20% from fill, GTC, expires 2026-08-03. Below the post-print low and below the 52-week low, so the position has room to be wrong before forced out.

The signal grades behind GEHC on cluster breadth (2 officers vs 3) but matches it on title quality (CEO + CFO is the strongest two-person combination). Sized for a clean signal in a story stock that’s been correctly punished. If the chronic portfolio recovers any of its run-rate the multiple compresses fast.

What would change my mind

• Q2 2026 earnings (2026-07-29) prints with a second cut to FY2026 revenue guidance. The bull case requires Q1 to be the trough.
• A 424B5 equity issuance off the existing shelf. Currently clean of dilution filings. An issuance at these levels would be a strong negative.
• Insider sales by Rademacher or Sethna in the next 60 days. Either reversing within the hold window would invalidate the buy signal.
• Loss of a major payer contract or visible PBM competitive win taking share at quarter-end checks.
• Stock breaks below $18.01 (the 52-week low) on volume without a bounce within five sessions.

Order details

Outcomes